Jessica Corson

Jessica Corson is the Vice President of Business Development at Mirati Therapeutics, where she oversees and executes the company’s strategy for inbound and outbound collaborative and partnership opportunities. She has been with Mirati in roles of increasing responsibility since March of 2013.

Jessica has a life science background coupled with broad business experience, gained through more than 15 years of transaction-focused and operational roles within the biotech industry. Her deal experience encompasses transactions that collectively value over $10B, including buy and sell-side product licensing and M&A deals, diagnostic collaborations, R&D alliances, and public financings.

Prior to joining Mirati, Jessica worked in the Business Development group at Amylin Pharmaceuticals, from 2006 until the company’s sale to Bristol-Myers Squibb (BMS) in 2012. During her tenure at Amylin, she played key roles as a deal team member in multiple strategic transactions, including the company’s $1B collaboration with Takeda, the $1.6B reacquisition of global rights to a blockbuster diabetes franchise from Eli Lilly, and ultimately, the sale of Amylin to BMS for $7B.

Early in her career, Jessica worked in a medicinal chemistry laboratory and later as a licensing associate for a research reagent company. Jessica received a B.S. in Biology from the University of California, San Diego and holds an MBA from the UCLA Anderson School of Management.